# Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

> **NCT06029309** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alvaro Alencar, MD** · enrollment: 27 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Tafasitamab

## Key facts

- **NCT ID:** NCT06029309
- **Lead sponsor:** Alvaro Alencar, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-03
- **Primary completion:** 2028-05-01
- **Final completion:** 2032-05-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06029309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06029309, "Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06029309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*